Evidence map›Paper›PMID 32746445›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021

Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress.

Jack E Henningfield, Sherecce Fields, James C Anthony, Lawrence S Brown, Carlos A Bolaños-Guzmán, Sandra D Comer, Richard De La Garza, Debra Furr-Holden, Albert Garcia-Romeu, Dorothy K Hatsukami and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Racial and ethnic socioenvironmental inequity and neuroimaging in psychiatry: a brief review of the past and recommendations for the future.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  3. Reply to Drs. Hart and Cadet: we agree-the challenges of increasing equity, diversity and inclusion include societal issues and actions now are vital.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jack E HenningfieldPinneyAssociates and The Johns Hopkins University School of Medicine, 4800 Montgomery Lane, Suite 400, Bethesda, MD, 20184, USA. jhenning@pinneyassociates.com.
Sherecce FieldsDepartment of Psychological & Brain Sciences, Texas A&M University, 4235 TAMU, College Station, TX, 77843, USA.ORCID http://orcid.org/0000-0002-6618-3394
James C AnthonyMichigan State University, College of Human Medicine, 909 Wilson Road Room B601, East Lansing, MI, 48824, USA.ORCID http://orcid.org/0000-0001-7176-0929
Lawrence S BrownSTART Treatment & Recovery Centers, 22 Chapel Street, Brooklyn, NY, 11201, USA.
Carlos A Bolaños-GuzmánDepartment of Psychological & Brain Sciences, Texas A&M University, 4235 TAMU, College Station, TX, 77843, USA.
Sandra D ComerColumbia University Irving Medical Center and the New York State Psychiatric Institute, 1051 Riverside Drive #120, New York, NY, 10032, USA.
Richard De La GarzaUniversity of New Mexico Health Sciences Center, College of Pharmacy, Albuquerque, NM, 87131, USA.
Debra Furr-HoldenMichigan State University, College of Human Medicine, 200 E First St., Flint, MI, 48503, USA.
Albert Garcia-RomeuThe Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
Dorothy K HatsukamiUniversity of Minnesota Medical School and Masonic Cancer Center, 717 Delaware St SE, Minneapolis, MN, 55414, USA.
Armin RaznahanNational Institute of Mental Health, 6001 Executive Boulevard, Bethesda, MD, 20892, USA.
Carlos A ZarateNational Institute of Mental Health, 6001 Executive Boulevard, Bethesda, MD, 20892, USA.

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Target validation of novel therapeutic agents in mood disordersZIAMH002927 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2010 to 2025
$37.1M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeuropharmacologyPsychopharmacologyEducational StatusHumansUnited StatesUniversities

Identifiers

PMID32746445
PMCPMC8115073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.